Tag Archive | "carboplatin"
Neck response to chemoradiotherapy
Source: Arch Otolaryngol Head Neck Surg. 2009;135(11):1133-1136 Author: Alexander Langerman, MD et al. Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer Objective: The role of neck dissection following chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer is an area of active debate. Patients who have a complete radiographic response may [...]
Continue reading...Oncolytics’ Phase III borrows adaptive design in SPA trial
Monday, October 5, 2009
Source: www.bioworld.com Author: Catherine Hollingsworth Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. The Phase III trial will be conducted in two stages and will cost an estimated $15 million, Matt Coffey, [...]
Continue reading...Oncolytics Biotech(R) Inc. collaborators present positive head and neck results in phase I/II combination
Monday, March 23, 2009
Source: pr-canada.net Author: press release Oncolytics Biotech Inc. announced that interim clinical results from its Phase I/II U.K. trial of Reolysin(R) combined with paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009. The principal [...]
Continue reading...New platinum-phosphate compounds kill ovarian vancer cells, other cancer cells
Saturday, November 22, 2008
Source: www.sciencedaily.com Author: staff A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published in the journal Proceedings of the National Academy of Sciences. The compounds could be less harmful than current cancer treatments on the market [...]
Continue reading...Virus accomplice helps drugs fight cancer
Friday, November 7, 2008
Source: www.newscientist.com Author: Andy Coghlan A virus that harmlessly infects most people at some time in their lives appears to help anti-cancer drugs destroy tumours, or at least keep them in check. Known as a reovirus, it destroys tumour cells because they lack the cellular machinery that keeps the virus in check in healthy cells. Results released last week [...]
Continue reading...Oncolytics reports positive results from phase I/II cancer studies
Tuesday, November 4, 2008
Source: www.pharmaceutical-business-review.com Author: staff Oncolytics Biotech has announced positive interim results in its Phase I and Phase II UK combination Reolysin and paclitaxel/carboplatin clinical trials for patients with advanced cancers. Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response, the company said. These results appear to confirm preclinical [...]
Continue reading...Oncolytics Biotech Inc. starts patient enrolment in U.S. phase 2 clinical trial investigating Reolysin(R) in combination with paclitaxel and carboplatin
Friday, September 12, 2008
Source: www.marketwatch.com Author: press release Oncolytics Biotech Inc. announced today that that it has started patient enrollment in a Phase 2 clinical trial using intravenous administration of Reolysin(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy & Research Center (CTRC) [...]
Continue reading...Platinum-based chemotherapy plus cetuximab in head and neck cancer
Thursday, September 11, 2008
Source: New England Journal of Medicine, Volume 359:1116-1127, September 11, 2008, Number 11 Authors: Jan B. Vermorken, M.D., Ph.D. et al. Background: Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of [...]
Continue reading...- Samuel Broder: Why Isn't There a Gardasil for Men?
- Snus news & other tobacco products
- High dosage brachytherapy obtains excellent results in head and neck tumors
- A vaccine debate once focused on sex shifts as boys join the target market
- Consistent evidence to support the use of xylitol- and sorbitol-containing chewing gum to prevent dental caries
- Bill would bar sales of dissolvable tobacco
- R. J. Reynolds introducing 'dissolvable' tobacco
- Smoking debate has become nicotine-delivery debate
- Israeli study sees link between oral cancer, cell phones
- Periodontitis associated with fourfold increased risk for squamous cell carcinoma of the head and neck
- hilllaguna: Negating that nicotine replacement therapies are p...
- OC Advocate: It comes a little surprise that this "test" which ...
- hilllaguna: By world medical treatment standards a diagnosis t...
- Oral Cancer Foundation News Team: After sending this retrospective look to major can...
- hilllaguna: The mathematical probably that you have been expos...
- Is it really about time? Overcoming the real barriers to complete oral cancer screening
- HPV-related cancer not confined to cervix
- Office-based ultrasound-guided FNA found to be superior in diagnosing head and neck lesions
- Why men’s health is a feminist issue
- BT Pharma secures EUR 13.1million (USD 17.7 million) in capital funding and changes its name to Genticel
- Cancer survivor tells his experience with smokeless tobacco
- Mayo oral cancer study shows full tumor genome
- Viagra, Cialis do more than arouse
- Avoid incense
- Transoral robotic surgery showed good oncologic, functional outcomes
Follow OCF on these social networking sites connect to us, get involved, spread the knowledge, help the cause, change the world.
Tuesday, November 17, 2009
0 Comments